Related Experiment Videos
Ultrastructural features of danazol-induced cholestasis: a case study
1Dipartimento di Medicina Clinica, Universita' di Roma "La Sapienza," Italy.
Ultrastructural Pathology
|September 1, 1996
Summary
Danazol can cause severe hepatocanalicular cholestasis, a rare liver condition. This cholestasis resolved after discontinuing danazol treatment, showing distinct ultrastructural liver changes.
Area of Science:
- Hepatology
- Pharmacology
- Toxicology
Background:
- Danazol is a synthetic steroid used to treat various medical conditions.
- Drug-induced liver injury (DILI) is a significant clinical concern.
- Cholestatic syndromes can arise from medication use.
Observation:
- A case study details severe cholestasis in a patient treated with danazol (300 mg/daily).
- Cholestasis developed after 3 months of treatment and resolved 2 months post-discontinuation.
- Liver enzymes showed minimal elevation despite high bilirubin and bile salt levels.
Findings:
- Light microscopy revealed centrolobular cholestasis without necrosis or bile ductule involvement.
- Ultrastructural analysis showed dilated bile canaliculi with microvillar damage and bile plugs.
- Hepatocyte organelles exhibited nonspecific alterations.
Implications:
- Danazol may induce a distinct form of severe hepatocanalicular cholestasis.
- This condition differs from the 'bland' cholestasis often seen with other anabolic steroids.
- Further research is needed to understand the mechanism of danazol-induced cholestasis.